Three-year follow-up of the use of transdermal 17β-estradiol matrix patches for the prevention of bone loss in early postmenopausal women

American Journal of Obstetrics and Gynecology

Volumn 184, Issue 2, 2001, Pages 32-40

  Delmas, P D ^a   Pornel, B ^d   Felsenberg, D ^e   Stakkestad, J A ^b   Radowicki, S ^f   Garnero, P ^a,b   Hardy, P ^c   Dain, M P ^c   Petitier, B ^c  

^a EDOUARD HERRIOT HOSPITAL   (France)

^b Synarc ^*

^c SANOFI PASTEUR   (France)

^d Brussels Menopause Center   (Belgium)

^e FREIE UNIVERSITÄT BERLIN   (Germany)

^f MEDICAL UNIVERSITY OF WARSAW   (Poland)

Author keywords

17 estradiol; Bone mineral density; Dual x ray absorptiometry; Menopause; Transdermal

Indexed keywords

ESTRADIOL;

ADULT; ARTICLE; BONE ATROPHY; BONE DENSITY; BONE MASS; BONE MINERAL; BONE TURNOVER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG FORMULATION; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; HUMAN; LUMBAR SPINE; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0035127898     PISSN: 00029378     EISSN: None     Source Type: Journal    
DOI: 10.1067/mob.2001.108328     Document Type: Article

References (23)

1. Management of postmenopausal osteoporosis
2. Hormone replacement therapy in the prevention and treatment of osteoporosis
3. Effect of estrogens on bone and other systems and hormonal substitute treatment
4. The epidemiology of osteoporosis
5. Hip and calcaneal bone loss increase with advancing age: Longitudinal results from the study of osteoporotic fractures
6. Bone turnover in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy
7. Matrix delivery transdermal 17β-estradiol for the prevention of bone loss in postmenopausal women
8. A dose-ranging trial of a matrix transdermal 17β-estra-diol for the prevention of bone loss in early postmenopausal women
9. Evaluation of the calcium content of diet by frequential self-questionnaire
10. Assessment of bone resorption with a new marker of collagen degradation in patients with metabolic bone disease
11. Assessment of the serum levels of bone alkaline phosphatase with a new immunoradiometric assay in patients with metabolic bone disease
12. Measurement of serum osteocalcin with a human-specific two-site immunoradiometric assay
13. Menopausal changes in bone remodeling
14. Preventive effects of transdermal 17β-estradiol on osteoporotic changes after surgical menopause: A two-year placebo-controlled trial
15. Urinary excretion of pyridinoline crosslinks correlates with bone turnover measured on lilac crest biopsy in patients with vertebral osteoporosis
16. Timing of post-menopausal estrogen for optimal bone mineral density
17. Estrogens in the prevention of osteoporosis in postmenopausal women
18. Long-term prevention of postmenopausal osteoporosis by oestrogen: Evidence for an increased bone mass after delayed onset of oestrogen treatment
19. Estrogen treatment of patients with established postmenopausal symptoms
20. Treatment of postmenopausal osteoporosis with transdermal estrogen
21. Inter-relationship of bone loss and its prevention, and fracture expression
22. The efficacy of long term prevention of osteoporosis by hormone replacement therapy (HRT) is variable according to skeletal sites: The OFELY study
23. Effect of 10 years' hormone replacement therapy on hone mineral content on postmenopausal women